Higher levels of CSF alpha-synuclein predict faster cognitive loss in Parkinson disease

March 11, 2014

The course of Parkinson disease (PD) can vary from gradual deterioration to precipitous decline in motor or cognitive function. Therefore identifying predictors of progression can benefit understanding of PD disease progression and impact management. Data from 304 PD patients followed for up to 8 years indicate that patients with higher cerebrospinal fluid (CSF) alpha-synuclein levels experienced faster cognitive decline in the following months, although no associations were found between alpha-synuclein levels and motor changes. The results are published in The American Journal of Pathology.

A characteristic pathological feature of PD is the presence of Lewy bodies, which are formed by intracellular deposits of the protein alpha-synuclein in neurons. Although several large studies have shown that alpha-synuclein levels are lower in the CSF of PD patients and those with related synucleinopathies compared to controls, its role in and dementia had been unexplored.

Researchers were able to access CSF samples from the deprenyl and tocopherol antioxidative therapy of Parkinsonism (DATATOP) study, which is the largest cohort assembled to date with longitudinal collection of biological fluids and clinical data from PD patients. "DATATOP subjects were recruited at early disease stages, without apparent signs of dementia and prior to needing dopamine-supplementing drugs, making this cohort ideal for studying PD progression," explains Jing Zhang, MD, PhD, Department of Pathology at the University of Washington School of Medicine (Seattle).

Cognitive performance and other clinical measures, including the United Parkinson Disease Rating Scale (UPDRS), Mini-Mental State Exam (MMSE), and Hoehn and Yahr scales, were assessed at the beginning of the study and subsequently every 6 months, with an average follow-up time of 1.8 years and maximum of 8 years. Data were separated into Phase I (the time between study entry and a clinician's determination that levodopa therapy was required) and Phase II (the time between initiation of levodopa therapy and the conclusion of follow-up). CSF samples were collected at the beginning of Phases I and II. Although the study began as a randomized trial that divided subjects into four treatment groups (placebo, deprenyl, alpha-tocopherol, and deprenyl/alpha-tocopherol), this was terminated early because positive effects of deprenyl were observed and all subjects then received deprenyl for approximately 18 months.

The investigators found that although alpha-synuclein levels decreased significantly over the course of the study, in agreement with previous studies lacking the longitudinal component, its values did not predict the worsening of motor symptoms (as measured by UPDRS) over Phase I or Phase II. "One possible explanation is that UPDRS reflects primarily deficits arising from nigrostriatal degeneration, whereas CSF alpha-synuclein levels are influenced by the whole brain and may serve as a proxy for total brain pathology," says Dr. Zhang.

The findings for cognition were quite different: Higher CSF alpha-synuclein levels predicted faster cognitive decline. The results were significant during Phase II. Analyses were controlled for age, sex, education, exposure to study drug, and prescribed dose of levodopa. The tests evaluated multiple modes of cognition, including verbal learning and memory and visuospatial working memory/processing speed. Similar trends were found for all tests.

"The finding that alpha-synuclein levels decrease as PD progresses, yet those with higher alpha-synuclein levels experience faster cognitive decline, is somewhat counterintuitive," comments Dr. Zhang. He and his colleagues, including first author, Tessandra Stewart, PhD, suggest that the decrease in CSF alpha-synuclein may be the result of a compensatory process, reflecting greater retention of the protein in the brain. This may allow damaged or degenerating neurons to maintain their function for longer than those who are less efficient at retaining alpha-synuclein.

Dr. Zhang points out that the unique value of this study derives from the ability to perform longitudinal assessments of cognition in PD patients over a long time period and access to data from a large cohort that began when patients were in the earliest stage of disease.

Explore further: SUMO defeats protein aggregates that typify Parkinson's disease

More information: "Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort," by Tessandra Stewart, Changqin Liu, Carmen Ginghina, Kevin C. Cain, Peggy Auinger, Brenna Cholerton, Min Shi, Jing Zhang, and the Parkinson Study Group DATATOP investigators (DOI: dx.doi.org/10.1016/j.ajpath.2013.12.007), The American Journal of Pathology, Volume 184, Issue 4 (April 2014)

Related Stories

SUMO defeats protein aggregates that typify Parkinson's disease

July 11, 2011
A small protein called SUMO might prevent the protein aggregations that typify Parkinson's disease (PD), according to a new study in the July 11, 2011, issue of The Journal of Cell Biology.

Five CSF markers differentiate dementia, parkinsonism

August 28, 2012
(HealthDay)—Levels of five different cerebrospinal fluid (CSF) biomarkers are able to improve differentiation between common dementia and parkinsonian disorders, according to a study published online Aug. 27 in the Archives ...

Bath scientists find clues to dementia and Parkinson's

November 7, 2013
A research team from our Department of Biology and Biochemistry has identified a possible target to reduce the levels of a protein called alpha-synuclein – linked to both Parkinson's disease and dementia with Lewy bodies.

Study identifies possible biomarker for Parkinson's disease

October 7, 2013
Although Parkinson's disease is the second most prevalent neurodegenerative disorder in the U.S., there are no standard clinical tests available to identify this widespread condition. As a result, Parkinson's disease often ...

PD-like sleep and motor problems observed in alpha-synuclein mutant mice

June 7, 2013
The presence of Lewy bodies in nerve cells, formed by intracellular deposits of the protein α-synuclein, is a characteristic pathologic feature of Parkinson's Disease (PD). In the quest for an animal model of PD that mimics ...

Research shows genetic evidence that new therapies targeting Parkinson's disease may cause harm

March 21, 2013
(Medical Xpress)—NorthShore University HealthSystem (NorthShore) and Mayo Clinic researchers have partnered on a study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein—a ...

Recommended for you

Good cells gone bad: Scientists discover PINK-SNO

November 21, 2017
A new study from The Scripps Research Institute (TSRI) is the first to show precisely how a process in nerve cells called the S-nitrosylation (SNO) reaction—which can be caused by aging, pesticides and pollution—may contribute ...

Genetic defects in the cell's 'waste disposal system' linked to Parkinson's disease

November 14, 2017
An international study has shed new light on the genetic factors associated with Parkinson's disease, pointing at a group of lysosomal storage disorder genes as potential major contributors to the onset and progression of ...

Parkinson's disease: A looming pandemic

November 13, 2017
New research shows that the number of people with Parkinson's disease will soon grow to pandemic proportions. In a commentary appearing today in the journal JAMA Neurology, University of Rochester Medical Center neurologist ...

Focused ultrasound shows promise for treating Parkinson's tremor

October 30, 2017
An initial test to determine if a scalpel-free form of brain surgery can reduce tremor caused by Parkinson's disease has produced encouraging results. Further research is warranted, the researchers conclude in a paper published ...

Novel technique explains herbicide's link to Parkinson's disease

October 23, 2017
Northwestern Medicine scientists have used an innovative gene editing technique to identify the genes that may lead to Parkinson's disease after exposure to paraquat, a commonly-used herbicide.

Data, technology drive new approaches to Parkinson's care

October 23, 2017
Complex, multi-system diseases like Parkinson's have long posed challenges to both scientists and physicians. University of Rochester Medical Center (URMC) researchers are now reaching for new tools, such as algorithms, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.